Application of high-throughput screening to identify a novel αIIb-specific small-molecule inhibitor of αIIbβ3-mediated platelet interaction with fibrinogen

Blood

Volumn 111, Issue 3, 2008, Pages 1248-1256

  Blue, Robert ^a   Murcia, Marta ^b   Karan, Charles ^a   Jiroušková, Markéta ^a   Coller, Barry S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; FIBRINOGEN; INTEGRIN; PROTEIN ALPHAIIB; PROTEIN ALPHAIIBBETA3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 38949130475     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-105544     Document Type: Article

References (56)

1. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell. 1991;65:359-362.
2. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol. 2005;17:509-516.
3. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104:1606-1615.
4. Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 1980;55:169-178.
5. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-297.
6. De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with the glycoprotein IIb/IIIa complex: its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest. 1986;77:1272-1277.
7. Gralnick HR, Williams SB, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood. 1984;64:797-800.
8. Coller BS, Mitchell WB, French DL. Hereditary Qualitative Platelet Disorders. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal J, eds. Williams Hematology. 7th Ed. New York, NJ: McGraw-Hill; 2005:1795-1831.
9. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest. 1997;100:S57-S60.
10. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol. 2000;35:1103-1115.
11. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59-67.
12. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res. 1983;29:249-255.
13. Lam SC, Plow EF, Smith MA, et al. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets. J Biol Chem. 1987;262:947-950.
14. Hettasch JM, Bolyard MG, Lord ST. The residues AGDV of recombinant gamma chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost. 1992;68:701-706.
15. Beacham DA, Wise RJ, Turci SM, Handin RI. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis. J Biol Chem. 1992;267:3409-3415.
16. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem. 1993;268:1058-1065.
17. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296:151-155.
18. Loftus JC, Plow EF, Frelinger AL III, et al. Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A. 1987;84:7114-7118.
19. Frelinger AL, III, Cohen I, Plow EF, et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990;265:6346-6352.
20. Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation- dependent epitope of human platelet glycoprotein IIIa. J Biol Chem. 1990;265:20594-20601.
21. Honda S, Tomiyama Y, Pelletier AJ, et al. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem. 1995;270:11947-11954.
22. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost. 2000;84:1095-1102.
23. Du XP, Plow EF, Frelinger AL, III et al. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991;65:409-416.
24. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
25. Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb/ IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol. 2000;36:1514-1519.
26. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 2002;106:379-385.
27. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des. 2004;10:1587-1596.
28. Hanson J, de Leval X, David JL, et al. Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:157-167.
29. Bassler N, Loeffler C, Mangin P, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol. 2007;27:e9-e15.
30. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 2005;127:53S-59S.
31. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood. 1983;61:99-110.
32. Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood. 1989;74:182-192.
33. Kutok JL, Coller BS. Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency. Thromb Haemost. 1994;72:964-972.
34. Artoni A, Li JH, Mitchell B, et al. Integrin beta3 regions controlling the binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A. 2004;101:13114-13120.
35. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
36. Shadle PJ, Ginsberg MH, Plow EF, Barondes SH. Platelet-collagen adhesion: inhibition by a monoclonal antibody that binds glycoprotein IIb. J Cell Biol. 1984;99:2056-2060.
37. Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol. 1995;130:441-450.
38. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4:67-73.
39. Fratantoni JC, Poindexter BJ. Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies. Am J Clin Pathol. 1990;94:613-617.
40. Law DA, Nannizzi-Alaimo L, Ministri K, et al. Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood. 1999;93:2645-2652.
41. Kouns WC, Hadvary P, Haering P, Steiner B. Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa. J Biol Chem. 1992;267:18844-18851.
42. Varon D, Lashevski I, Brenner B, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J. 1998;135:S187-S193.
43. Wang W, Wu Q, Pasuelo M, McMurray JS, Li C. Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization. Bioconjug Chem. 2005;16:729-734.
44. Murcia M, Ortiz AR. Virtual screening with flexible docking and COMBINE-based models: application to a series of factor Xa inhibitors. J Med Chem. 2004;47:805-820.
45. Hartigan JA. Clustering Algorithms. New York, NY: John Wiley & Sons; 1975.
46. De LC. The use of trypsin for the determination of cellular viability. Exp Cell Res. 1965;40:186-188.
47. Patel D, Vaananen H, Jirouskova M, et al. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood. 2003;101:929-936.
48. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33-38.
49. Poncz M, Eisman R, Heidenreich R, et al. Structure of the platelet membrane glycoprotein IIb: homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem. 1987;262:8476-8482.
50. Di Braccio Mario Roma G, Leoncini G. 1,2-Fused pyrimidines VII. 3-(Dialkylamino)-1Hpyrimido[ 1,2-a]quinolin-1-ones and 2-(dialkylamino)-4H- pyrido[2,1-a]isoquinolin-4-ones as antiplatelet compounds. Eur J Med Chem. 1995;30:27-38.
51. Leoncini G, Signorello MG, Roma G, Di BM. Effect of 2-(1-piperazinyl)-4H- pyrido[1,2-a]pyrimidin-4-one (AP155) on human platelets in vitro. Biochem Pharmacol. 1997;53:1667-1672.
52. Roma G, Braccio MD, Carrieri A et al. Coumarin, chromone, and 4(3H)-pyrimidinone novel bicyclic and tricyclic derivatives as antiplatelet agents: synthesis, biological evaluation, and comparative molecular field analysis. Bioorg Med Chem. 2003;11:123-138.
53. Leoncini G, Signorello MG, Bruzzese D, et al. Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1- benzopyran-2-one (RC414). Biochem Pharmacol. 2004;67:911-918.
54. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Thromb Haemost. 1996;75:503-509.
55. Honda S, Tomiyama Y, Aoki T, et al. Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. Blood. 1998;92:3675-3683.
56. Kouns WC, Kirchhofer D, Hadvary P, et al. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539-2547.